Technology

Abera has developed a unique vaccine platform based on Gram-negative bacteria and derived Outer Membrane Vesicles (OMVs) that can be decorated on the surface with multiple antigens of choice at a high density. Abera’s platforms have several unique characteristics as explained on the right.

Abera’s display technology allows the simultaneous surface expression of multiple different antigens per bacterium or derived membrane vesicle. Multivalency is an important feature in obtaining protection against many infectious diseases. It also allows the generation of broadly protecting vaccines that induce immunity to multiple pathogens or pathogen variants at the same time.

Abera’s vaccine platforms can be administered nasally or orally and are thus ideally suited to induce not only systemic but also local mucosal responses to prevent transmission of pathogens. This creates a strong advantage compared to injected vaccines as approximately 80 percent of infectious diseases spread via the mucosa where a majority of the body’s immune system is concentrated. In addition, needle-free administration has a lower demand for trained medical personnel and equipment, which makes it more cost-efficient compared to injection of the vaccine.

Current vaccines are expensive due to complex manufacturing processes. In contrast, Abera’s bacterial-based vaccines can be designed and manufactured in 14-30 days. The platform enables production of large quantities of the vaccine at a low-cost through a simple fermentation process.

Platform

Bera-D

Bera-D (Display) is a highly efficient platform for the display of antigens at the cell surface of Gram-negative bacteria.

Bera-V

Bera-V (Vesicles) is Abera’s platform for production of vaccines based on outer membrane vesicles (OMVs). OMVs are small vesicles that naturally shed from Gram-negative bacteria. Unlike the parental bacteria, OMVs cannot replicate and thus have an improved safety profile.

Bera-S

Bera-S (Secretion) is Abera’s platform for efficient secretion of antigens into the culture medium of Gram-negative bacteria for the production of subunit vaccines.